• Pharming presented positive Phase II topline data for leniolisib in genetic primary immunodeficiencies with immune dysregulation at ESID 2026.
• Study showed clinical improvements across key signs of immune dysregulation, supporting use beyond APDS; treatment was generally well tolerated.
• All participants who finished the trial chose to continue on leniolisib in a long-term extension study, supporting durability and retention.
• Management flagged a separate Phase II readout in common variable immunodeficiency expected in November, shaping plans for a registrational program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610140200OMX_____CNEWS_EN_GNW1001277884_en) on October 14, 2026, and is solely responsible for the information contained therein.